Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;131(5):1138-1146.
doi: 10.1002/lary.29084. Epub 2020 Sep 22.

Systemic Bevacizumab (Avastin) for Juvenile-Onset Recurrent Respiratory Papillomatosis: A Systematic Review

Marisa A Ryan  1 , Grace R Leu  2 , Patrick A Upchurch  3   4 , David E Tunkel  1 , Jonathan M Walsh  1 , Emily F Boss  1
Affiliations

Systemic Bevacizumab (Avastin) for Juvenile-Onset Recurrent Respiratory Papillomatosis: A Systematic Review

Marisa A Ryan et al. Laryngoscope. 2021 May.

Abstract

Objectives: Juvenile onset recurrent respiratory papillomatosis (JORRP) can cause severe or disseminated disease. Surgical treatment may be inadequate. Systemic bevacizumab has shown initial success for severe JORRP. The objective of this systematic review was to assess usage, effectiveness, and safety of this treatment.

Methods: We searched PubMed, Embase, and Web of Science for studies of humans with JORRP treated with systemic bevacizumab. Two researchers independently reviewed the studies to determine inclusion and aggregate data on patient characteristics, dosing protocols, treatment response, adverse events, and level of evidence.

Results: Of 80 identified articles, 12 studies were included detailing 20 distinct cases. At a mean age of 12.8 years (range = 1-43 years) patients received initial dosing of 5 to 10 mg/kg of bevacizumab followed by ongoing doses at a mean 3-week intervals (range = 2-5 weeks). All patients had clinically significant disease reduction with reduced need for surgery. Six patients (30%) had complete response in at least one involved anatomic site. Eleven (55%) required no surgery after initiating treatment. There was recurrence in all four patients whose treatment was stopped, but had rapid improvement with treatment resumption. Six (30%) experienced mild or moderate adverse events.

Conclusions: Marked improvement in severe JORRP has been reported from systemic bevacizumab. Treatment protocols vary, and treatment discontinuation was not feasible in any reported patient. Based on currently available data, systemic bevacizumab can be considered for severe JORRP as it appears to be well tolerated and effective. A clinical trial could enhance the understanding of its safety and efficacy for this indication. Laryngoscope, 131:1138-1146, 2021.

Keywords: Avastin; Bevacizumab; human papillomavirus; juvenile onset recurrent respiratory papillomatosis; recurrent respiratory papillomatosis.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. RRP Foundation Patient Data Analysis. RRP patient stats. Available at: http://www.rrpf.org/patientstats.html. Accessed January 11, 2019.
    1. Chow LT, Broker TR, Steinberg BM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010;118:422-449.
    1. Rodriguez H, Cuestas G, Alvarez M, Monaje M. Recurrent respiratory papillomatosis with lung and chest wall involvement: a rare complication in an adolescent. Acta Otorrinolaringol Esp 2018;69:110-113.
    1. Mohr M, Schliemann C, Biermann C, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014;8:1912-1918.
    1. Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 2017;127:2225-2229.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources